Shark Tank India judge and Shaadi.com founder Anupam Mittal has cautioned against the growing trend of using Ozempic for weight loss. In a LinkedIn post, he warned that if the drug becomes as casually used for fat loss as Eno is for indigestion, it could undermine sustainable fitness and lifestyle changes.
The launch of Ozempic in India has sparked widespread debate, with many viewing it as a quick fix for weight loss. While the drug is primarily prescribed for Type 2 diabetes, its off-label use for slimming has gained popularity globally, especially among celebrities.
Anupam Mittal, angel investor and Shark Tank India judge, expressed concern over this trend, urging Indians to avoid “shortcut fitness.” He emphasized that true health requires consistent lifestyle changes rather than reliance on pharmaceutical solutions.
Key Highlights:
-
Mittal’s Warning: He compared Ozempic’s rising popularity to Eno, cautioning against casual overuse for fat loss.
-
Drug Context: Ozempic is a GLP-1 receptor agonist, designed for diabetes management but increasingly used for weight reduction.
-
Market Impact: In India, Ozempic is priced around ₹8,800 per month, with analysts projecting a potential ₹1,000 crore annual market.
-
Lifestyle Reminder: Mittal stressed that fitness cannot be achieved through “jugaad” (shortcuts), highlighting the importance of diet and exercise.
-
Industry Debate: The drug’s popularity raises questions about responsible use, regulation, and long-term health impacts.
Mittal’s remarks underline the need for balanced health practices and caution against turning medical treatments into everyday lifestyle hacks.
Sources: LiveMint, Shotlee, Startuppedia